ArticleJournal of immunology (Baltimore, Md. : 1950)2012
The role of tuberous sclerosis complex 1 in regulating innate immunity.
Article in Journal of immunology (Baltimore, Md. : 1950), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 72 citations in OpenAlex.
- Rapamycin unbalances the polarization of human macrophages to M1.Immunology · 2013Trial
- mTORC2 is crucial for regulating the recombinant Mycobacterium tuberculosis CFP-10 protein-induced phagocytosis in macrophages.BMC immunology · 2025Article
- Macrophage energy metabolism in cardiometabolic disease.Molecular and cellular biochemistry · 2025Review
- Tuberous Sclerosis Complex: New Insights into Pathogenesis and Therapeutic Breakthroughs.Life (Basel, Switzerland) · 2025Review
- Article
- RNA Expression of MMP12 Is Strongly Associated with Inflammatory Bowel Disease and Is Regulated by Metabolic Pathways in RAW 264.7 Macrophages.International journal of molecular sciences · 2024Article
- Reprogramming tumor-associated macrophages to outcompete endovascular endothelial progenitor cells and suppress tumor neoangiogenesis.Immunity · 2023Article
- Loss of myeloid Tsc2 predisposes to angiotensin II-induced aortic aneurysm formation in mice.Cell death & disease · 2022Article
- AKT Isoforms in Macrophage Activation, Polarization, and Survival.Current topics in microbiology and immunology · 2022Article
- Modulation of mTOR Signaling in Cardiovascular Disease to Target Acute and Chronic Inflammation.Frontiers in cardiovascular medicine · 2022Review
- Role of TSC1 in physiology and diseases.Molecular and cellular biochemistry · 2021Review
- Slit2-Mediated Metabolic Reprogramming in Bone Marrow-Derived Macrophages Enhances Antitumor Immunity.Frontiers in immunology · 2021Article
- Transcriptomic analysis reveals that mTOR pathway can be modulated in macrophage cells by the presence of cryptococcal cells.Genetics and molecular biology · 2021Article
- The Role of TSC1 in the Macrophages AgainstFrontiers in cellular and infection microbiology · 2020Article
- NLRP3 and mTOR Reciprocally Regulate Macrophage Phagolysosome Formation and Acidification AgainstFrontiers in cell and developmental biology · 2020Article
- Review
- Regulation of Metabolic Disease-Associated Inflammation by Nutrient Sensors.Mediators of inflammation · 2018Review
- Mammalian Target of Rapamycin Inhibition inFrontiers in immunology · 2018Article
- Harnessing the mTOR Pathway for Tuberculosis Treatment.Frontiers in microbiology · 2018Review
- mTORC2 Signaling Selectively Regulates the Generation and Function of Tissue-Resident Peritoneal Macrophages.Cell reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
The mechanisms that control TLR-induced responses, including endotoxin tolerance, have been not well understood. The tuberous sclerosis complex 1 (TSC1) is a tumor suppressor that inhibits the mammalian target of rapamycin (mTOR). We show in this study that deficiency of TSC1 results in enhanced activation of not only mTOR complex 1 (mTORC1), but also JNK1/2, following LPS stimulation in macrophages. TSC1-deficient macrophages produce elevated proinflammatory cytokines and NO in response to multiple TLR ligands. Such enhanced TLR-induced responses can be inhibited by reducing mTORC1 and JNK1/2 activities with chemical inhibitors or small hairpin RNA, suggesting that TSC1 negatively controls TLR responses through both mTORC1 and JNK1/2. The impact of TSC1 deficiency appeared not limited to TLRs, as NOD- and RIG-I/MDA-5-induced innate responses were also altered in TSC1-deficient macrophages. Furthermore, TSC1 deficiency appears to cause impaired induction of endotoxin tolerance in vitro and in vivo, which is correlated with increased JNK1/2 activation and can be reversed by JNK1/2 inhibition. Our results reveal a critical role of TSC1 in regulating innate immunity by negative control of mTORC1 and JNK1/2 activation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.